CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02151526
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:41.721375+00:00
Published At: 2020-03-10T00:00:00+00:00
Record Updated At: 2022-04-26
Results Posted At: 2020-03-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Beta-Thalassemia Major", "Sickle Cell Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-04-26"
protocolSection.identificationModule.nctId: "NCT02151526"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the \u03b2-Hemoglobinopathies (Sickle Cell Anemia and \u03b2-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral \u03b2-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-03-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.